Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals, Inc. (VRPX)
:VRPX
VRPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $42.25
Previous CloseN/A
Volume440.71K
Average Volume (3M)15.82K
Market Cap
$24.85K
Enterprise Value-$1.06M
Total Cash (Recent Filing)$1.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 19, 2025EPS Estimate
-5.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-128.83
Shares Outstanding1,242,504
10 Day Avg. Volume16,952
30 Day Avg. Volume15,821
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.68
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap-42.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Virpax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Safety ProfileThe Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.
Study ResultsProbudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.
Bears Say
Financial ConstraintsInsufficient capital to materially advance into Phase 2 studies for both Probudur and Envelta.
Leadership InstabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
Regulatory ComplianceVirpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until a specific date to regain compliance.
Options Prices
Currently, No data available
---
Ownership Overview
0.12%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.98% Public Companies and
Individual Investors
VRPX FAQ
What was Virpax Pharmaceuticals, Inc.’s price range in the past 12 months?
Virpax Pharmaceuticals, Inc. lowest stock price was $0.01 and its highest was $42.25 in the past 12 months.
What is Virpax Pharmaceuticals, Inc.’s market cap?
Virpax Pharmaceuticals, Inc.’s market cap is $24.85K.
When is Virpax Pharmaceuticals, Inc.’s upcoming earnings report date?
Virpax Pharmaceuticals, Inc.’s upcoming earnings report date is May 19, 2025 which is 68 days ago.
How were Virpax Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Virpax Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Virpax Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Virpax Pharmaceuticals, Inc. pay dividends?
Virpax Pharmaceuticals, Inc. does not currently pay dividends.
What is Virpax Pharmaceuticals, Inc.’s EPS estimate?
Virpax Pharmaceuticals, Inc.’s EPS estimate is -5.25.
How many shares outstanding does Virpax Pharmaceuticals, Inc. have?
Virpax Pharmaceuticals, Inc. has 1,242,504 shares outstanding.
What happened to Virpax Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Virpax Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in VRPX
Virpax Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.95%
12-Months-Change
Fundamentals
Return on Equity
-2364.82%
Trailing 12-Months
Asset Growth
-83.84%
Trailing 12-Months
Company Description
Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals (VRPX) is a clinical-stage pharmaceutical company focused on developing novel drug delivery systems to enhance the efficacy and safety of existing therapeutics. The company primarily operates in the pharmaceutical sector, specializing in pain management, neurological disorders, and anti-viral therapies. By leveraging proprietary delivery technologies, Virpax aims to optimize the delivery of active pharmaceutical ingredients, ultimately improving patient outcomes.